Business Context and Reporting Period
Company: SelectQuote, Inc. (SLQT)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2026
Business Overview: SelectQuote is a technology-enabled, direct-to-consumer (DTC) distribution platform for insurance policies and healthcare services. The company operates three reportable segments: Senior (Medicare Advantage and Supplement), Healthcare Services (SelectRx pharmacy, Healthcare Select, and SelectPatient Management), and Life (Term and Final Expense). The Auto & Home segment is now reported as "All Other" and is de-emphasized. The company leverages proprietary AI and machine learning to optimize lead acquisition, agent routing, and customer lifetime value (LTV).
Key Financial Metrics
| Metric (in thousands) | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Revenue | $1,618,499 | $1,526,594 | $1,321,776 |
| Net Income (Loss) | $62,189 | $47,580 | $(34,125) |
| Net Income Attributable to Common Shareholders | $(11,649) | $25,032 | $(34,125) |
| Adjusted EBITDA | $109,132 | $126,254 | $116,993 |
| Operating Cash Flow | $31,885 | $(11,666) | $15,236 |
| Total Debt Obligations | $370,168 | $385,112 | N/A |
| Cash, Cash Equivalents, and Restricted Cash | $21,677 | $37,066 | $42,690 |
Revenue Mix (2026): Pharmacy revenue ($830.9M) now exceeds Commissions and other services ($787.6M), representing 51% and 49% of total revenue, respectively.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 6% year-over-year (YoY) to $1.62 billion, driven primarily by a 14% increase in Pharmacy revenue ($102.1M increase) due to higher prescription volume and the full-year contribution of the new Olathe, Kansas fulfillment facility.
- Senior Segment Decline: Senior segment revenue decreased 4% YoY to $575.9M. This was caused by a 4% decrease in approved policies and a significant drop in production bonuses and marketing development funds following the Annual Enrollment Period (AEP).
- Life Segment Growth: Life segment revenue increased 8% YoY to $186.0M, driven by growth in both final expense and term life policies.
- Profitability: Net income increased 31% to $62.2M, though Net Income Attributable to Common Shareholders turned negative ($(11.6)M) due to $73.8M in accumulated dividends and accretion on Senior Non-Convertible Preferred Stock.
- Interest Expense: Net interest expense decreased 44% to $44.5M, largely due to the repayment of previous term loans using proceeds from the Senior Non-Convertible Preferred Stock issuance in February 2025.
- Warrant Liability: The company recognized a non-cash gain of $55.8M from the change in fair value of warrant liabilities, reflecting a decrease in the company's stock price.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Strategy
Management is prioritizing the expansion of Healthcare Services (SelectRx) as a higher-growth opportunity while de-emphasizing Auto & Home. Strategic investments in AI (contact center voice technology, AI-assisted software) are underway to improve agent productivity and reduce acquisition costs. The company aims to maximize Lifetime Value (LTV) of commissions through improved retention and cross-selling.
Unusual Items
- Loss on Extinguishment of Debt: An $8.7M loss was recognized in 2026 related to the refinancing of the Senior Secured Credit Facility.
- Inflation Reduction Act Impact: Beginning in calendar year 2026, the company began receiving manufacturer refunds under the Medicare Prescription Drug Inflation Rebate Program. These are reported as a reduction of Cost of Goods Sold (COGS) rather than revenue, impacting gross margin presentation.
Risks and Contingencies
- NYSE Listing Compliance: On March 19, 2026, the company received notice of non-compliance with NYSE listing standards due to the average closing price falling below $1.00 for 30 consecutive days. The company plans to seek stockholder approval for a reverse stock split to cure the deficiency. Failure to regain compliance could result in delisting.
- Legal Proceedings: The company is a defendant in a qui tam action (DOJ Action) alleging violations of the False Claims Act regarding sales and marketing practices. The court denied motions to dismiss on most counts in March 2026. The company denies the allegations and is defending vigorously.
- Carrier Concentration: Revenue is heavily concentrated among a few carriers. For 2026, UnitedHealthcare (39%), Humana (13%), and Aetna (12%) accounted for 64% of total revenue.
- Seasonality: A significant portion of revenue (33% in 2026) is generated in the second quarter due to the Medicare Annual Enrollment Period (AEP).
Investor Verification Checklist
- Reverse Stock Split Approval: Verify the outcome of the proposed reverse stock split to determine if the company will regain NYSE listing compliance.
- DOJ False Claims Act Litigation: Monitor the status of the qui tam action and potential financial exposure from treble damages or penalties.
- Pharmacy Margin Sustainability: Assess the impact of the Inflation Reduction Act manufacturer refunds on reported COGS and the long-term margin profile of the SelectRx business.
- Senior Segment Persistency: Review policy lapse rates and renewal commission assumptions, as these are critical to the LTV model and revenue recognition in the Senior segment.
- Preferred Stock Obligations: Evaluate the cash flow impact of the 14.5% dividend rate on the $350M Senior Non-Convertible Preferred Stock, which significantly reduces net income available to common shareholders.